The discovery of checkpoint inhibition and the 2011 FDA approval of ipilimumab in metastatic malignant melanoma, a monoclonal antibody that blocks CTLA-4, marked the beginning of a new era in oncology. Here, CTLA4 is linked to metastatic melanoma.